(Q52865572)

9 May 2018

title

Echocardiography in functional midgut neuroendocrine tumors: When and how often. (English)

1 reference

9 May 2018

1 reference

Javier G Castillo

1 reference

9 May 2018

Tara Naib

series ordinal

1 reference

9 May 2018

Jerome S Zacks

series ordinal

1 reference

9 May 2018

David H Adams

series ordinal

1 reference

9 May 2018

publication date

28 October 2017

1 reference

9 May 2018

Reviews in Endocrine and Metabolic Disorders

published in

1 reference

9 May 2018

volume

1 reference

9 May 2018

issue

1 reference

9 May 2018

page(s)

411-421

1 reference

9 May 2018

A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Carcinoid heart disease in patients without hepatic metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Fibrosis and carcinoid syndrome: from causation to future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Flushing in (neuro)endocrinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Drug-induced valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

A matter of the heart: myocardial metastases in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Serotonin receptors and heart valve disease--it was meant 2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Surgical management of carcinoid heart valve disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Refractory carcinoid syndrome: a review of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

A Nomogram to Assess Small-Intestinal Neuroendocrine Tumor (‘Carcinoid’) Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Early and Late Outcomes of Surgical Treatment in Carcinoid Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Current concepts in diagnosis and perioperative management of carcinoid heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Prevalence of rheumatic heart disease detected by echocardiographic screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Consensus guidelines for the management and treatment of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Factors associated with progression of carcinoid heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Point-of-care ultrasonography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Handheld echocardiographic screening for rheumatic heart disease by non-experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Focused cardiac ultrasound: recommendations from the American Society of Echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Plasma Serotonin in Heart Failure: Possible Marker and Potential Treatment Target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Serotonin Signaling Through the 5-HT1B Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Variability of biomarkers in patients with chronic heart failure and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Cardiac Surgery for Carcinoid Heart Disease: A Weapon Not to Be Misused.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Quadruple valve surgery in carcinoid heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Drug-induced fibrotic valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Three-dimensional visual guidance improves the accuracy of calculating right ventricular volume with two-dimensional echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Assessment of right ventricular function with Doppler echocardiographic indices derived from tricuspid annular motion: comparison with radionuclide angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Evaluation of right ventricular dysfunction by myocardial strain echocardiography in patients with intestinal carcinoid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Update on management of midgut neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

Early and Late Results of Valvular Surgery for Carcinoid Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-017-9434-Z

21 January 2018

Carcinoid heart disease

1 reference

12 December 2020

Surgical management of left-sided carcinoid heart disease.

1 reference

12 December 2020

Clinical chemistry of serotonin and metabolites

1 reference

12 December 2020

2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

1 reference

12 December 2020

Carcinoid Heart Disease without Severe Tricuspid Valve Involvement

1 reference

12 December 2020

Atrial fibrillation in carcinoid heart disease: The role of serotonin. A review of the literature

1 reference

12 December 2020

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers

1 reference

12 December 2020

Outcomes, risks and complications of cardiac surgery for carcinoid heart disease

1 reference

12 December 2020

Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities

1 reference

12 December 2020

Carcinoid Heart Disease: The Challenge of the Unknown Known

1 reference

12 December 2020

The effects of serotonin on the electrophysiological properties of atrioventricular node during an experimental atrial fibrillation

1 reference

12 December 2020

Absence of the tricuspid valve due to severe carcinoid heart disease

1 reference

12 December 2020

The 5-HT2B receptor: a main cardio-pulmonary target of serotonin

1 reference

12 December 2020

10.1007/S11154-017-9434-Z

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018